Marvel Biosciences Corp. (MRVL.V)
CAD 0.16
(10.34%)
CAD 0.16
(10.34%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -887.51 Thousand CAD | 35.55% |
| 2022 | -1.37 Million CAD | -124.62% |
| 2021 | -613.09 Thousand CAD | -131.18% |
| 2020 | -265.2 Thousand CAD | 0.0% |
| 2019 | - CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | -30.04 Thousand CAD | 30.96% |
| 2024 Q2 | -43.51 Thousand CAD | 79.44% |
| 2024 Q1 | -211.66 Thousand CAD | 65.78% |
| 2023 Q2 | -5737.00 CAD | 35.39% |
| 2023 FY | -887.51 Thousand CAD | 35.55% |
| 2023 Q3 | -254.36 Thousand CAD | -4333.71% |
| 2023 Q4 | -618.53 Thousand CAD | -143.17% |
| 2023 Q1 | -8879.00 CAD | 97.18% |
| 2022 Q1 | -241.27 Thousand CAD | -112.28% |
| 2022 FY | -1.37 Million CAD | -124.62% |
| 2022 Q4 | -315.19 Thousand CAD | -465.14% |
| 2022 Q2 | -764.92 Thousand CAD | -217.04% |
| 2022 Q3 | -55.77 Thousand CAD | 92.71% |
| 2021 Q2 | -105.8 Thousand CAD | 48.19% |
| 2021 Q1 | -204.19 Thousand CAD | 0.0% |
| 2021 FY | -613.09 Thousand CAD | -131.18% |
| 2021 Q3 | -189.45 Thousand CAD | -79.06% |
| 2021 Q4 | -113.65 Thousand CAD | 40.01% |
| 2020 FY | -265.2 Thousand CAD | 0.0% |
| 2019 FY | - CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Arch Biopartners Inc. | -128.99 Thousand CAD | -588.04% |
| Covalon Technologies Ltd. | 14.36 Million CAD | 106.18% |
| Hemostemix Inc. | -223.00 CAD | -397889.238% |
| Universal Ibogaine Inc. | 1.07 Million CAD | 182.883% |
| Kane Biotech Inc. | 109.47 Thousand CAD | 910.739% |
| MedMira Inc. | -434.91 Thousand CAD | -104.068% |
| NervGen Pharma Corp. | -145 Thousand CAD | -512.067% |
| XORTX Therapeutics Inc. | -188.54 Thousand CAD | -370.723% |